載入...
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
Accurate identification of patients likely to achieve long-progression-free survival (PFS) after chemoimmunotherapy is essential given the availability of less toxic alternatives, such as ibrutinib. Fludarabine, cyclophosphamide, and rituximab (FCR) achieved a high response rate, but continued relap...
Na minha lista:
| 發表在: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Society of Hematology
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4760129/ https://ncbi.nlm.nih.gov/pubmed/26492934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-09-667675 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|